The Etro Studies
Explore Innovation. Contribute to Science.
What is the Etro Studies Program?
The Etro Studies are a family of Phase III clinical trials, and a program of firsts: the first head-to-head studies in Ulcerative Colitis (UC), and the first Phase III program to use standardized, centralized endoscopic scoring in Crohn’s disease and UC.
The Etro Studies will examine the safety and efficacy of etrolizumab in patients who are still experiencing symptoms of Crohn’s disease or UC despite being previously treated with corticosteroids, immunosuppressants, and/or tumor necrosis factor (TNF) inhibitors. Some studies will evaluate etrolizumab in patients who are anti-TNF naïve, and others in patients who have had an inadequate response, loss of response, or intolerance to anti-TNF therapy.
The Etro Studies will compare etrolizumab to placebo, infliximab, or adalimumab. Parts of these studies are double- blinded and will last for up to 82 weeks. The open-label extension studies for UC and Crohn’s will provide study medication to eligible patients who meet the safety criteria.
Read more about the Etro Studies.